Xconomy | National - Business + Technology in the Exponential Economy

Archives

by in
Entry Blogger Date Location
Gloucester Pharma Wins FDA Approval of Drug for Rare Skin Cancer Luke Timmerman 11/05/09 Boston
Dendreon Files FDA Application, DxBox Reaches Turning Point, ISB to Do 100 Genomes, & More Seattle-Area Life Sciences News Luke Timmerman 11/05/09 Seattle
Amylin Forms Global Alliance in Obesity Drug Development; TEDMED’s Show Will Go On, Sequenom Sued for Civil Fraud, & More San Diego Biotech News Bruce V. Bigelow 11/05/09 San Diego
Vertex and Ironwood Drugs Fare Well in Clinical Trials, Pulmatrix Breathes in $30.2M, IRobot Launches Healthcare Unit, & More Boston-Area Life Sciences News Rebecca Zacks 11/04/09 Boston
Dendreon Files Provenge Application to FDA Ahead of Schedule, Now It’s Time to Wait Luke Timmerman 11/02/09 Seattle
Amylin, Lilly’s Byetta Wins FDA Approval as Standalone Therapy, Without Combo Drugs Luke Timmerman 10/30/09 San Diego
UK’s Enigma Looks to San Diego, Life Gets Sweeter for Senomyx, Arena Says Obesity Drug Is Not “Wimpy,” & More San Diego Life Sciences News Denise Gellene 10/29/09 San Diego
Stryker Biotech Division Indicted for FDA Fraud by Massachusetts Grand Jury Luke Timmerman 10/28/09 Boston
Interlace Gets FDA Clearance Ryan McBride 10/28/09 Boston
UK’s Enigma Diagnostics to Establish U.S. Headquarters in San Diego Bruce V. Bigelow 10/27/09 San Diego
Arena Positions Weight Loss Drug as the One That Won’t Raise Your Blood Pressure Luke Timmerman 10/27/09 San Diego
ZymoGenetics’ Former Medical Boss Leads Rival Startup, ProFibrix, With Drug For Bleeding Luke Timmerman 10/26/09 Seattle
Five Red Flags of a Biotech, Pathway Medical Learns Lessons, Amgen Faces FDA Delay, & More Seattle-Area Life Sciences News Luke Timmerman 10/22/09 Seattle
Antigenics Shares Plummet as Cancer Vaccine Application Rejected in Europe Luke Timmerman 10/21/09 Boston
Pathway Medical Learns Lessons During Tougher Than Expected First Year on Market Luke Timmerman 10/20/09 Seattle
Amgen’s Dmab Faces FDA Delay Luke Timmerman 10/19/09 Seattle
Top 10 Highlights from FiReGlobal: Michael Dell, Lee Hartwell, Irwin Jacobs, and More Gregory T. Huang 10/16/09 Seattle
Alkermes Anti-Addiction Drug Fares Well in Clinical Trials, Amgen Takes Aim at Drug-Development Success Rate, & More Boston-Area Life Sciences News Rebecca Zacks 10/14/09 Boston
Six Tips on How to Spot a Winning Biotech, From Dendreon Co-Founder Chris Henney Luke Timmerman 10/14/09 Seattle
Wireless Industry Foresees Capacity Constraints, Algae-Based Biofuels Still a Decade Away, Xconomy San Diego Marks its First Anniversary, & More San Diego BizTech News Bruce V. Bigelow 10/13/09 San Diego
Amgen’s Seattle and Boston Teams Seek to Boost Biotech Hit Rate 20 to 30 Percent Luke Timmerman 10/09/09 National
Public Biotechs’ Finances Foundering, Epizyme Banks $32M, Paratek Cuts Deal with Novartis, & More Boston-Area Life Sciences News Rebecca Zacks 10/09/09 Boston
Justice Department Joins Sequenom Probe, Accumetrics Raises $16.5, Transdel’s Topical Pain Reliever Gets Mixed Results, & More San Diego Life Sciences News Denise Gellene 10/08/09 San Diego
Gary West on San Diego’s West Wireless Health Institute and ‘Always On’ Medicine Bruce V. Bigelow 10/07/09 San Diego
DC Matters, But Biotech Can’t Neglect City Hall David Miller 10/07/09 Seattle
Gen-Probe Pays $60M for Prodesse Bruce V. Bigelow 10/06/09 San Diego
Genzyme Drug Fails to Win FDA Nod Luke Timmerman 10/06/09 Boston
Transdel’s Topical Pain Reliever Falls Short on One Goal, Hits Another Luke Timmerman 10/06/09 San Diego
“Don’t Touch My Bags If You Please, Mr. Customs Man” Stewart Lyman 10/05/09 Seattle
Marval Biosciences, San Diego’s Latest Virtual Biomedical Startup, Raises $2.5M to Develop Next-Generation Contrast Agents for Medical Imaging Bruce V. Bigelow 10/02/09 San Diego
Page 1 of 14 next page »
    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009, Xconomy, Inc. XCONOMY is a registered service mark of Xconomy, Inc. All rights reserved.
Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.